Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05340621
Title NAUTILUS: OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors OnKure, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
CTCA Phoenix, part of City of Hope Phoenix Arizona 85027 United States Details
University of California, San Francisco San Francisco California 94143 United States Details
University of Florida Health Cancer Center Gainesville Florida 32610 United States Details
Emory University Winship Cancer Institute Atlanta Georgia 30322 United States Details
CTCA Atlanta, part of City of Hope Newnan Georgia 30265 United States Details
CTCA Chicago, part of City of Hope Zion Illinois 60099 United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Henry Ford Health System Detroit Michigan 48202 United States Details
Memorial Sloan-Kettering Cancer Center New York New York 10065 United States Details
Sarah Cannon Research Institute Nashville Tennessee 37203 United States Details
University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
University of Virginia Health System Charlottesville Virginia 22908 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field